Learning outcomes
By the end of this lesson you should be able to: distinguish the three drug groups of thrombosis — antiplatelet agents, anticoagulants and thrombolytics — and say what each does to the evolving clot; describe the mechanism, monitoring, onset and reversal agent for heparin, low-molecular-weight heparin, warfarin and the direct oral anticoagulants; state the principal indications, including non-valvular atrial fibrillation and venous thromboembolism; recognise heparin-induced thrombocytopenia and its management; and weigh the contraindications that decide whether a thrombolytic can be given in an acute coronary occlusion or an ischaemic stroke.
Prerequisites
Lessons 1 to 6, and the coagulation cascade from the physiology course — platelets, thrombin, fibrin and the vitamin-K-dependent clotting factors II, VII, IX and X.
The big idea
Haemostasis has two arms. Platelets aggregate at the site of injury to form the primary plug, and the coagulation cascade lays fibrin on that plug to stabilise it as a thrombus. Antiplatelet drugs weaken the first arm and are arterial drugs; anticoagulants weaken the second and are venous and stasis drugs; thrombolytics dissolve the fibrin of an already-established clot and are emergency rescue agents. Choosing the wrong arm is a classic prescribing error: warfarin prevents stent thrombosis poorly, and clopidogrel prevents pulmonary embolism not at all.
Antiplatelet drugs
| Drug | Mechanism | Reversibility | Clinical use |
|---|---|---|---|
| Aspirin | Irreversibly inhibits platelet COX-1, so thromboxane A2 falls and the platelet cannot aggregate; the anucleate platelet cannot replace the enzyme | Lasts the life of each platelet (7 to 10 days of turnover) | Secondary prevention of vascular events; low-dose for thrombosis prophylaxis after stents |
| Clopidogrel | Irreversibly blocks the P2Y12 ADP receptor on the platelet | Waits for new platelets (about a week) | With aspirin as dual antiplatelet therapy after acute coronary syndromes and stenting |
| Ticagrelor | Reversibly blocks the same P2Y12 receptor, so offset is faster and not dependent on turnover | Reverses as the drug is cleared | Alternative to clopidogrel where thrombotic risk is highest |
| Dipyridamole | Raises platelet cyclic AMP; commonly combined with aspirin | Short | Secondary prevention after ischaemic stroke |
Watch outThe irreversibility of aspirin explains two clinical facts: a single dose affects platelets for the whole week it takes to replace them, and aspirin is stopped about a week before elective surgery, not the day before. Clopidogrel has the same recovery time course.
Anticoagulants
| Drug | Mechanism | Monitoring and onset | Reversal |
|---|---|---|---|
| Unfractionated heparin | Binds antithrombin III and accelerates its inhibition of thrombin and factor Xa; the large molecule does not cross the placenta | Intravenous, monitored by APTT ratio, half-life about an hour, immediate action | Protamine sulfate, given as a titrated dose |
| Low-molecular-weight heparin | The same antithrombin acceleration, but predominantly anti-factor-Xa activity | Subcutaneous, weight-based dosing, no routine monitoring outside pregnancy and renal failure | Protamine only partially reverses it |
| Warfarin | Inhibits vitamin K epoxide reductase, so the functional clotting factors II, VII, IX and X fall, and proteins C and S fall too | Oral, onset over days, monitored by INR with a target of 2.0 to 3.0 (2.5 to 3.5 for mechanical valves) | Vitamin K restores synthesis; four-factor prothrombin complex concentrate or FFP replaces immediately |
| Dabigatran | Direct thrombin inhibitor | Oral, fixed dose, no routine monitoring, partly renally cleared | Idarucizumab, an antibody fragment that neutralises dabigatran |
| Apixaban, rivaroxaban, edoxaban | Direct factor Xa inhibitors | Oral, fixed dose, no routine monitoring, largely hepatically cleared | Andexanet alfa where available, otherwise prothrombin complex concentrate |
Warfarin is the awkward survivor: it needs INR monitoring, it interacts with every cytochrome P450 inducer and inhibitor (rifampicin, amiodarone, many antibiotics) and with dietary vitamin K, it is teratogenic and causes skin necrosis in the first weeks through the protein C paradox, and it is the only oral agent licensed for a mechanical heart valve. The direct oral anticoagulants avoid all of that and at least halve intracranial haemorrhage, which is why they have displaced warfarin for non-valvular atrial fibrillation and venous thromboembolism — but they are renally cleared, so renal function and age decide the dose.
Worked example: two patients with the same atrial fibrillation
Two patients present with atrial fibrillation at a ventricular rate of 120 and both feel breathless. The patient with non-valvular fibrillation is given apixaban, because stroke prevention matches warfarin with fewer intracranial haemorrhages; the patient with a mechanical mitral valve is given warfarin to a target INR of 2.5 to 3.5, because the direct oral anticoagulants failed their trial in mechanical valves and warfarin remains the only licensed choice. Rate control is identical — a beta-blocker or digoxin — but the anticoagulant is not interchangeable, and the decision turns on the valve.
Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia is an immune reaction: antibodies against the complex of platelet factor 4 with heparin activate the platelets, so the platelet count falls by more than half from baseline even as the patient forms new venous and arterial thromboses. It typically begins days five to ten after heparin starts. The management is to stop every heparin product including line flushes, never to transfuse platelets into a prothrombotic storm, and to anticoagulate with a non-heparin agent such as argatroban, danaparoid or a direct oral anticoagulant. Low-molecular-weight heparin is less prone to the reaction but still causes it, so both heparins are stopped.
NoteThe clinical signature is a falling platelet count with clotting, not bleeding — a paradoxical thrombosis. A heparin-treated patient whose platelet count halves on day six, or who develops a new thrombosis while anticoagulated, has the diagnosis until the antibody assay confirms it.
Thrombolytics
Thrombolytics convert plasminogen to plasmin and dissolve fibrin. Alteplase, reteplase and tenecteplase are recombinant tissue plasminogen activators given as weight-based doses; streptokinase is the older streptococcal derivative, is antigenic, and should not be repeated after the first exposure. The indications are time-critical: occlusion of a coronary artery in ST-elevation myocardial infarction within twelve hours of symptom onset, acute ischaemic stroke with a disabling deficit within the treatment window once haemorrhage is excluded by scan, and massive pulmonary embolism with haemodynamic collapse. Where primary percutaneous coronary intervention is available within twelve hours it is superior to lysis for the myocardial infarction.
| Indication | Agent and route | Essential precondition |
|---|---|---|
| ST-elevation myocardial infarction | Tenecteplase or alteplase intravenously | No haemorrhage risk that outweighs the benefit; PCI within the time window is the superior option |
| Acute ischaemic stroke | Alteplase intravenously | Computed tomography excluding haemorrhage, onset within the treatment window, blood pressure controlled |
| Massive pulmonary embolism | Alteplase with heparin | Sustained hypotension or cardiac arrest attributable to the embolus |
| Selected extensive deep venous thrombosis | Alteplase, catheter-directed or systemic | Limb-threatening iliofemoral clot in a patient with low bleeding risk |
Watch outThe contraindications to thrombolysis are absolute: active internal bleeding, recent haemorrhagic stroke or any stroke within three months, recent major surgery or head injury, suspected aortic dissection, and a bleeding diathesis. Miss one and the lytic kills by the intracranial haemorrhage it causes — which is why the stroke protocol scans before the needle and the consent conversation happens at the same time.
Common mistakes
Watch outSaying heparin and warfarin are interchangeable because both stop clotting. Heparin acts immediately through antithrombin and is titrated; warfarin takes days to work through reduced synthesis of protein-based factors, and its first days can be prothrombotic as protein C falls before the factors do — which is why heparin bridges the start of warfarin in acute thrombosis.
Watch outPrescribing a direct oral anticoagulant for a mechanical heart valve. The dabigatran trial in mechanical valves was stopped early for excess thrombosis and bleeding; warfarin to a higher INR target is the standard of care.
Watch outForgetting reversal for the bleeding patient going to theatre. Warfarin is replaced immediately by four-factor prothrombin complex concentrate and restored by vitamin K; dabigatran is neutralised by idarucizumab. For the factor Xa inhibitors, the timing of the last dose decides most bleeds in practice.
Watch outStopping aspirin too early after coronary stenting, or too late before surgery. Immediate stent thrombosis is lethal, so the surgeon's demand to stop antiplatelets is weighed against the interval since the stent was placed and the kind of stent.
Check your understanding
Why is heparin rather than warfarin used on day one of an acute deep vein thrombosis?
A heparin-treated patient's platelet count halves on day six and a new clot appears in the other leg. What has happened and what is the management?
Which patient receives apixaban rather than warfarin, and why?
Multiple choice
Which anticoagulant is the drug of choice for a patient with a mechanical mitral valve?
Which is the reversal agent for dabigatran?
Which finding suggests heparin-induced thrombocytopenia?
Which is an absolute contraindication to thrombolysis for an acute ischaemic stroke?
Which statement about aspirin is correct?